News

FDA Approves Linagliptin for Type 2 Diabetes


 

FROM THE FDA

The Food and Drug Administration has approved linagliptin, a dipeptidyl peptidase 4 (DPP-4) inhibitor, for the treatment of type 2 diabetes, the agency announced in a May 2 statement.

Linagliptin, in a tablet formulation, is approved for improving blood glucose control in adults with type 2 diabetes, in combination with diet and exercise. In eight double-blind, placebo-controlled studies of about 3,800 patients with type 2 diabetes, those treated with linagliptin showed improvements in blood glucose control compared to those on placebo, according to the statement.

Linagliptin has been studied alone or in combination with other drugs used to treat type 2 diabetes, including metformin, glimepiride, and pioglitazone, the statement said. It will be marketed as Tradjenta, by Boehringer Ingelheim Pharmaceuticals and Eli Lilly.

At press time, neither company had posted a news release announcing the approval.

Recommended Reading

Hypoglycemia in Older Diabetics Could Point to Cognitive Impairment
MDedge Family Medicine
Testosterone Replacement Associated with Lower Mortality in Type 2 Diabetes
MDedge Family Medicine
Clinical Presentation May Determine Costs in Critical Limb Ischemia
MDedge Family Medicine
Liraglutide Beats Other Therapies for Lowering HbA1c Levels
MDedge Family Medicine
Age, Diabetes Affect Arthrodesis Outcomes in Charcot Patients
MDedge Family Medicine
Endocrine Society Releases Guidelines on Pituitary Incidentalomas
MDedge Family Medicine
Ultrasound Shows Promise in Wound Healing
MDedge Family Medicine
Denosumab Bone Health Benefits Persist After 5 Years
MDedge Family Medicine
Study: Diabetes Linked With Cancer and Cancer Mortality Risk
MDedge Family Medicine
Task Force Finds Little Guidance For Charcot Foot Tx
MDedge Family Medicine